Citi Upgrades Raptor Pharmaceuticals (RPTP) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
January 25, 2016 7:05 AM ESTFive Patents for PROCYSBI Now Listed in FDA Orange Book
Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old
NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that a U.S. PROCYSBI patent, number 9,233,077, is now listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent, entitled Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same, covers the enteric coated micro-bead formulation of PROCYSBI as well as... More
